|
Gene: PSMD1 |
Gene summary for PSMD1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PSMD1 | Gene ID | 5707 |
Gene name | proteasome 26S subunit, non-ATPase 1 | |
Gene Alias | P112 | |
Cytomap | 2q37.1 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q99460 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5707 | PSMD1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 5.08e-06 | 5.73e-01 | -0.0811 |
5707 | PSMD1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.31e-03 | 3.50e-01 | -0.1954 |
5707 | PSMD1 | A015-C-203 | Human | Colorectum | FAP | 3.78e-21 | -3.55e-01 | -0.1294 |
5707 | PSMD1 | A015-C-204 | Human | Colorectum | FAP | 4.17e-05 | -3.00e-01 | -0.0228 |
5707 | PSMD1 | A002-C-201 | Human | Colorectum | FAP | 6.29e-05 | -2.41e-01 | 0.0324 |
5707 | PSMD1 | A002-C-203 | Human | Colorectum | FAP | 1.42e-03 | -1.29e-01 | 0.2786 |
5707 | PSMD1 | A001-C-119 | Human | Colorectum | FAP | 2.73e-05 | -3.95e-01 | -0.1557 |
5707 | PSMD1 | A001-C-108 | Human | Colorectum | FAP | 2.34e-15 | -2.87e-01 | -0.0272 |
5707 | PSMD1 | A002-C-205 | Human | Colorectum | FAP | 7.58e-12 | -3.77e-01 | -0.1236 |
5707 | PSMD1 | A001-C-104 | Human | Colorectum | FAP | 3.97e-03 | -2.33e-01 | 0.0184 |
5707 | PSMD1 | A015-C-006 | Human | Colorectum | FAP | 1.43e-06 | -2.85e-01 | -0.0994 |
5707 | PSMD1 | A015-C-106 | Human | Colorectum | FAP | 6.35e-07 | -2.46e-01 | -0.0511 |
5707 | PSMD1 | A002-C-114 | Human | Colorectum | FAP | 1.20e-10 | -4.16e-01 | -0.1561 |
5707 | PSMD1 | A015-C-104 | Human | Colorectum | FAP | 7.00e-24 | -4.08e-01 | -0.1899 |
5707 | PSMD1 | A001-C-014 | Human | Colorectum | FAP | 1.34e-07 | -2.98e-01 | 0.0135 |
5707 | PSMD1 | A002-C-016 | Human | Colorectum | FAP | 2.07e-13 | -2.93e-01 | 0.0521 |
5707 | PSMD1 | A015-C-002 | Human | Colorectum | FAP | 1.82e-05 | -3.29e-01 | -0.0763 |
5707 | PSMD1 | A001-C-203 | Human | Colorectum | FAP | 9.21e-09 | -2.73e-01 | -0.0481 |
5707 | PSMD1 | A002-C-116 | Human | Colorectum | FAP | 3.27e-22 | -4.00e-01 | -0.0452 |
5707 | PSMD1 | A014-C-008 | Human | Colorectum | FAP | 8.57e-10 | -5.06e-01 | -0.191 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000863718 | Oral cavity | OSCC | apoptotic mitochondrial changes | 78/7305 | 107/18723 | 1.06e-12 | 4.78e-11 | 78 |
GO:190305217 | Oral cavity | OSCC | positive regulation of proteolysis involved in cellular protein catabolic process | 92/7305 | 133/18723 | 1.60e-12 | 6.90e-11 | 92 |
GO:00482852 | Oral cavity | OSCC | organelle fission | 265/7305 | 488/18723 | 3.22e-12 | 1.27e-10 | 265 |
GO:007233120 | Oral cavity | OSCC | signal transduction by p53 class mediator | 107/7305 | 163/18723 | 4.75e-12 | 1.83e-10 | 107 |
GO:001082117 | Oral cavity | OSCC | regulation of mitochondrion organization | 97/7305 | 144/18723 | 4.78e-12 | 1.83e-10 | 97 |
GO:000155816 | Oral cavity | OSCC | regulation of cell growth | 228/7305 | 414/18723 | 1.74e-11 | 6.09e-10 | 228 |
GO:001095220 | Oral cavity | OSCC | positive regulation of peptidase activity | 123/7305 | 197/18723 | 2.12e-11 | 7.21e-10 | 123 |
GO:003243619 | Oral cavity | OSCC | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 66/7305 | 90/18723 | 3.76e-11 | 1.23e-09 | 66 |
GO:007190010 | Oral cavity | OSCC | regulation of protein serine/threonine kinase activity | 201/7305 | 359/18723 | 3.90e-11 | 1.27e-09 | 201 |
GO:005254820 | Oral cavity | OSCC | regulation of endopeptidase activity | 235/7305 | 432/18723 | 4.35e-11 | 1.40e-09 | 235 |
GO:200006020 | Oral cavity | OSCC | positive regulation of ubiquitin-dependent protein catabolic process | 75/7305 | 107/18723 | 6.67e-11 | 2.06e-09 | 75 |
GO:00002801 | Oral cavity | OSCC | nuclear division | 237/7305 | 439/18723 | 9.62e-11 | 2.90e-09 | 237 |
GO:200102017 | Oral cavity | OSCC | regulation of response to DNA damage stimulus | 131/7305 | 219/18723 | 3.21e-10 | 8.72e-09 | 131 |
GO:005123518 | Oral cavity | OSCC | maintenance of location | 182/7305 | 327/18723 | 6.16e-10 | 1.58e-08 | 182 |
GO:000183616 | Oral cavity | OSCC | release of cytochrome c from mitochondria | 46/7305 | 59/18723 | 1.17e-09 | 2.87e-08 | 46 |
GO:001063918 | Oral cavity | OSCC | negative regulation of organelle organization | 190/7305 | 348/18723 | 2.12e-09 | 4.97e-08 | 190 |
GO:004518520 | Oral cavity | OSCC | maintenance of protein location | 65/7305 | 94/18723 | 3.00e-09 | 6.88e-08 | 65 |
GO:19033227 | Oral cavity | OSCC | positive regulation of protein modification by small protein conjugation or removal | 88/7305 | 138/18723 | 3.24e-09 | 7.39e-08 | 88 |
GO:00457879 | Oral cavity | OSCC | positive regulation of cell cycle | 173/7305 | 313/18723 | 3.28e-09 | 7.44e-08 | 173 |
GO:001095019 | Oral cavity | OSCC | positive regulation of endopeptidase activity | 107/7305 | 179/18723 | 1.38e-08 | 2.78e-07 | 107 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05012 | Colorectum | AD | Parkinson disease | 147/2092 | 266/8465 | 2.53e-27 | 8.48e-25 | 5.41e-25 | 147 |
hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
hsa05016 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
hsa05020 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
hsa05014 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
hsa05022 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
hsa03050 | Colorectum | AD | Proteasome | 29/2092 | 46/8465 | 3.87e-08 | 6.18e-07 | 3.94e-07 | 29 |
hsa05017 | Colorectum | AD | Spinocerebellar ataxia | 60/2092 | 143/8465 | 3.78e-06 | 4.35e-05 | 2.78e-05 | 60 |
hsa050121 | Colorectum | AD | Parkinson disease | 147/2092 | 266/8465 | 2.53e-27 | 8.48e-25 | 5.41e-25 | 147 |
hsa050101 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
hsa050161 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
hsa050201 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
hsa050141 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
hsa050221 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
hsa030501 | Colorectum | AD | Proteasome | 29/2092 | 46/8465 | 3.87e-08 | 6.18e-07 | 3.94e-07 | 29 |
hsa050171 | Colorectum | AD | Spinocerebellar ataxia | 60/2092 | 143/8465 | 3.78e-06 | 4.35e-05 | 2.78e-05 | 60 |
hsa050128 | Colorectum | FAP | Parkinson disease | 80/1404 | 266/8465 | 2.04e-08 | 6.20e-07 | 3.77e-07 | 80 |
hsa050108 | Colorectum | FAP | Alzheimer disease | 105/1404 | 384/8465 | 3.74e-08 | 1.04e-06 | 6.33e-07 | 105 |
hsa050228 | Colorectum | FAP | Pathways of neurodegeneration - multiple diseases | 117/1404 | 476/8465 | 2.81e-06 | 4.47e-05 | 2.72e-05 | 117 |
hsa050148 | Colorectum | FAP | Amyotrophic lateral sclerosis | 91/1404 | 364/8465 | 1.84e-05 | 2.36e-04 | 1.44e-04 | 91 |
Page: 1 2 3 4 5 6 7 8 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PSMD1 | SNV | Missense_Mutation | rs745401053 | c.164N>A | p.Arg55Gln | p.R55Q | Q99460 | protein_coding | tolerated(0.19) | benign(0) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
PSMD1 | SNV | Missense_Mutation | c.2809N>A | p.Glu937Lys | p.E937K | Q99460 | protein_coding | tolerated(0.74) | possibly_damaging(0.899) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PSMD1 | SNV | Missense_Mutation | c.2812N>A | p.Glu938Lys | p.E938K | Q99460 | protein_coding | tolerated(0.7) | possibly_damaging(0.899) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR | |
PSMD1 | SNV | Missense_Mutation | c.2755N>C | p.Glu919Gln | p.E919Q | Q99460 | protein_coding | tolerated(0.14) | possibly_damaging(0.543) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
PSMD1 | SNV | Missense_Mutation | c.2098G>A | p.Glu700Lys | p.E700K | Q99460 | protein_coding | deleterious(0.02) | benign(0.141) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PSMD1 | SNV | Missense_Mutation | c.898N>C | p.Glu300Gln | p.E300Q | Q99460 | protein_coding | tolerated(0.24) | benign(0.001) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
PSMD1 | SNV | Missense_Mutation | c.2177C>A | p.Ala726Asp | p.A726D | Q99460 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-E9-A295-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
PSMD1 | insertion | Frame_Shift_Ins | novel | c.850dupA | p.Thr284AsnfsTer12 | p.T284Nfs*12 | Q99460 | protein_coding | TCGA-A2-A0EN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
PSMD1 | insertion | Frame_Shift_Ins | novel | c.2407_2408insCTTTTCTT | p.Lys803ThrfsTer36 | p.K803Tfs*36 | Q99460 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
PSMD1 | insertion | Frame_Shift_Ins | novel | c.268_269insC | p.Val90AlafsTer3 | p.V90Afs*3 | Q99460 | protein_coding | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5707 | PSMD1 | NA | OPROZOMIB | OPROZOMIB | ||
5707 | PSMD1 | NA | inhibitor | CHEMBL325041 | BORTEZOMIB | |
5707 | PSMD1 | NA | inhibitor | CARFILZOMIB | CARFILZOMIB | |
5707 | PSMD1 | NA | BORTEZOMIB | BORTEZOMIB | 24524217 | |
5707 | PSMD1 | NA | inhibitor | CHEMBL2103884 | OPROZOMIB | |
5707 | PSMD1 | NA | BORTEZOMIB | BORTEZOMIB | ||
5707 | PSMD1 | NA | BORTEZOMIB | BORTEZOMIB | ||
5707 | PSMD1 | NA | CARFILZOMIB | CARFILZOMIB | 24524217 | |
5707 | PSMD1 | NA | MLN-9708 | IXAZOMIB CITRATE | ||
5707 | PSMD1 | NA | inhibitor | CHEMBL451887 | CARFILZOMIB |
Page: 1 2 |